Trump’s proposed changes to pharmacy benefit rules are a gift to drug companies and the pharma industry

The proposed changes in the Pharmacy Benefit Exchange (PBFE) rules would allow companies to sell more prescriptions for cheaper prices.

The proposed rules, which were released last week by the Federal Trade Commission, allow the companies to negotiate prices for more than 1.5 million prescription drugs, a significant expansion of the market.

That would create an incentive for the industry to compete.

The rules allow companies that sell more than 2 million prescriptions a year to make up the difference in prices.

This could create a lot of uncertainty and confusion for consumers.

The companies would be allowed to negotiate drug prices at a more competitive rate than what Medicare pays them, and that would make it easier for consumers to make informed decisions.

For example, a company that sells more than 3 million prescriptions for one brand of a drug, such as a generic version of the same medication, could negotiate prices at the same rate as the generic manufacturer.

And if they decide to lower the price for the generic version, they could lower the prices for the brand of the brand.

The new rules also would give drug makers more flexibility in their pricing plans.

For example, they can use more generic versions of their medications, or they can buy generic versions for smaller quantities.

The new rules could also allow drug companies to price drugs more accurately.

The changes are intended to help prevent prescription drug abuse, which accounts for more Americans dying from drug overdoses than from any other cause, according to a Centers for Disease Control and Prevention (CDC) report.

But the rules could be a boon to drug makers and drug companies would have to compete for more patients and prescriptions, which could drive up prices. 

Under the proposed changes, the price of prescription drugs would be tied to the average price paid by patients, which is a much higher number than what the average consumer pays.

This means that if the average drug costs $100 more per prescription than what a typical patient pays, that will drive up the price.

If the average is $300 or less, that price increase will not be reflected in the price that consumers pay for the drug. 

The proposed changes also would allow for drug makers to increase the number of generic versions available to pharmacies.

Under current rules, drug companies have to offer at least one generic version for every brand of drug they offer.

Under the proposed rules they could offer as many as 10 generic versions, a number that would increase from about 2.5 generic versions per brand to more than 20. 

Pharmaceutical companies are not the only ones that are hoping to benefit from the proposed rule changes.

The proposed rule change also will allow for companies to raise prices on drugs that are cheaper than their competitors.

For instance, drug makers can increase the price on a generic brand of an insulin, a drug that is widely used to treat diabetes.

The proposed rules also will permit drug makers with an existing pharmacy network to offer cheaper versions of insulin, or allow for generic versions to be available in a smaller number of pharmacies.

These changes could make it more difficult for companies with no pharmacy network that offer generic versions or that do not have a pharmacy network in the market to compete against larger drug companies that offer brand-name versions.

The rule changes are scheduled to take effect on Oct. 15.

If they are approved, the proposed pharmacy benefit exchange rules would be put into effect on Nov. 1, according the agency.